FDA approves ribociclib with an aromatase inhibitor and ribociclib and letrozole co-pack for early high-risk breast ...
FDA approves Kisqali with an aromatase inhibitor and Kisqali Femara Co-Pack for early high-risk breast cancer On September 17, 2024, the Food and Drug Administration approved ribociclib (Kisqali, Novartis Pharmaceuticals Corporation) with an aromatase …